Health Care & Life Sciences » Pharmaceuticals | Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc. | Ownership

Companies that own Intra-Cellular Therapies Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
8,204,457
15%
2,390
0.02%
06/30/2018
The Vanguard Group, Inc.
3,805,629
6.96%
113,072
0%
06/30/2018
BlackRock Fund Advisors
3,544,769
6.48%
10,618
0%
06/30/2018
Bellevue Asset Management AG
2,279,900
4.17%
-11,100
0.72%
06/30/2018
Wasatch Advisors, Inc.
1,908,231
3.49%
25,889
0.27%
06/30/2018
Dimensional Fund Advisors LP
1,356,720
2.48%
159,860
0.01%
06/30/2018
Citadel Advisors LLC
1,321,724
2.42%
167,197
0.04%
06/30/2018
Schroder Investment Management North America, Inc.
1,193,594
2.18%
1,193,594
0.14%
06/30/2018
Samlyn Capital LLC
990,281
1.81%
335,938
0.54%
06/30/2018
Millennium Management LLC
950,505
1.74%
376,537
0.03%
06/30/2018

About Intra-Cellular Therapies

View Profile
Address
430 East 29th Street
New York New York 10016
United States
Employees -
Website http://www.intracellulartherapies.com
Updated 07/08/2019
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease.